Literature DB >> 26265225

Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?

Daniel A Goldstein1, Bassel F El-Rayes2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26265225      PMCID： PMC4571811          DOI： 10.1634/theoncologist.2015-0028

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

1.  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Authors:  Lee S Schwartzberg; Fernando Rivera; Meinolf Karthaus; Gianpiero Fasola; Jean-Luc Canon; J Randolph Hecht; Hua Yu; Kelly S Oliner; William Y Go
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

3.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors:  Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

4.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Authors:  C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

5.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Authors:  Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

6.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

7.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

8.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

9.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

10.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Authors:  Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544
View more
  8 in total

1.  Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.

Authors:  Peter B Bach
Journal:  Oncologist       Date:  2015-08-11

Review 2.  Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.

Authors:  Simon B Zeichner; Daniel A Goldstein; Christine Kohn; Christopher R Flowers
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 3.  Financial toxicity and implications for cancer care in the era of molecular and immune therapies.

Authors:  George Tran; S Yousuf Zafar
Journal:  Ann Transl Med       Date:  2018-05

Review 4.  Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Authors:  Leonard B Saltz
Journal:  Cancer J       Date:  2016 May-Jun       Impact factor: 3.360

Review 5.  A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.

Authors:  Kristen K Ciombor; Tanios Bekaii-Saab
Journal:  Oncologist       Date:  2017-10-11

Review 6.  Adjuvant therapy for pancreas cancer in an era of value based cancer care.

Authors:  Daniel H Ahn; Terence M Williams; Daniel A Goldstein; Bassel El-Rayes; Tanios Bekaii-Saab
Journal:  Cancer Treat Rev       Date:  2015-11-24       Impact factor: 12.111

7.  Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.

Authors:  Bradley J Monk; Philip E Lammers; Thomas Cartwright; Ira Jacobs
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-28

8.  Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.

Authors:  Zhi Peng; Xingduo Hou; Yangmu Huang; Tong Xie; Xinyang Hua
Journal:  BMC Cancer       Date:  2020-10-13       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.